Skip to main content
Deciphera
Deciphera
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin

News

News

Archive
May 27, 2021

Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

Archive
May 4, 2021

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results

Archive
April 27, 2021

Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021

Archive
March 2, 2021

Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference

Archive
February 18, 2021

Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Archive
February 9, 2021

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results

Archive
February 4, 2021

Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

Archive
February 2, 2021

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021

Archive
January 11, 2021

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones

Archive
January 5, 2021

Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Pagination

  • First page ‹‹ First
  • Previous page ‹ Prev
  • …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Current page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • …
  • Next page Next ›
  • Last page Last ››
Displaying 101 - 110 of 271
Deciphera
twitter linkedin
contact us
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement
  • Compliance Hotline
  • Consent Manager

© 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo.

Back to top